Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Bank of America Analyst Says
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price boosted by investment analysts at Bank of America ...
Q1 Earnings Estimate for AXSM Issued By Leerink Partnrs
Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a research report issued ...
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
Neurology Advisor3h
FDA Approves Symbravo for Acute Treatment of Migraine in Adults
The US Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
kalkinemedia47m
How Are Institutional Investors Adjusting Their Holdings in Axsome Therapeutics (NASDAQ:AXSM)
Highlights,Multiple financial firms have provided positive ratings for Axsome Therapeutics, reflecting confidence in the ...
kalkinemedia45m
Lululemon (NASDAQ:LULU) Expands Market Reach with Strong Financial Backing
Highlights,Oppenheimer raised its price expectation for Lululemon, reflecting financial performance adjustments.,Financial ...